(Alliance News) - Molecular diagnostics group Yourgene Health PLC on Monday said it had won two national framework contract awards for Covid-19 testing services.
Public Health England's National Microbiology Framework is appointing suppliers to framework agreements for four lots. International molecular diagnostics group Yourgene has so far been awarded contracts for lots 1 and 4, both covering diagnostic goods and services.
Lot 4 is a GBP15 billion framework over a period of four years by multiple successful bidders, with only 50 companies appointed.
Manchester-based Yourgene was awarded the contract for its Clarigene SARS-CoV-2 assay and its Covid-19 testing service located in Manchester.
Yourgene said the contract for lot 1 covers the supply of in-vitro diagnostic medical devices and associated services, as well as clinical laboratory testing services delivered through Yourgene Genomic Services. The contract is expected to last an initial two years, with options to extend by up to a further two years.
The PHE tender was opened in November last year and sought to appoint suppliers to a multi-lot national microbiology framework agreement. Genedrive PLC, a molecular testing business, also was successful in its tender to provide services.
"Yourgene considers that the successful framework award, for which there was a competitive tender process, lends significant credibility to the Clarigene product and to the company's Covid-19 testing services," said Chief Executive Lyn Rees.
"More broadly, we expect the award to support business development outside the scope of this agreement with a growing network of commercial partners, addressing privately funded testing in healthcare and workplace settings," she added.
Yourgene were up 9.6% at 16.44 pence in London on Monday afternoon. Genedrive was up 8.8% at 72.90p.
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Genedrive (GDR)